# APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct07667296/  
OnCo record `nct07667296` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of APG-157 run by Aveta Biomics, Inc., not yet recruiting.

## Summary

APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT07667296 by Aveta Biomics, Inc., with 826 participants planned, started 2026-07. Conditions recorded: Head and Neck Cancer, Head and Neck (HNSCC), Oropharyngeal, Oral Cavity, Oral Cavity Carcinoma, Oropharynx Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma. Interventions recorded: APG-157, Surgery, Radiation/Chemotherapy and Radiation/Chemotherapy.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07667296
- Phase: 3
- Setting: A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Sponsor: Aveta Biomics, Inc.
- Enrolled: 826

## Sources

- ClinicalTrials.gov NCT07667296: https://clinicaltrials.gov/study/NCT07667296

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/), [Oropharyngeal cancer (tonsil and base of tongue)](https://onco.cc/cancers/oropharyngeal-cancer/)
- drugs: [APG-157](https://onco.cc/drugs/apg-157/)
- companies: [Aveta Biomics](https://onco.cc/companies/aveta-biomics/)

---
JSON: https://onco.cc/api/v1/entities/nct07667296.json